The GD3S-knockdown-mediated enhancement of gefitinib cytotoxicity and reduction of gefitinib IC50 in TNBC cells (MDA-MB468) suggests that GD3S regulation is a useful target for breast cancer therapy. This evidence concerns the gene ST8SIA1 and breast carcinoma.